Morgan Stanley Reiterates Overweight on Sarepta Therapeutics, Maintains $165 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $165.
June 21, 2024 | 5:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Matthew Harrison has reiterated an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $165.
The reiteration of an Overweight rating and a maintained price target of $165 by a reputable analyst from Morgan Stanley is likely to positively impact investor sentiment and could lead to a short-term increase in SRPT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100